Rybelsus is oral semaglutide, a GLP-1 receptor agonist indicated for adults with type 2 diabetes to improve glycemic control and to reduce major adverse cardiovascular events in high-risk patients. The label describes semaglutide as a GLP-1 analogue that stimulates insulin secretion and lowers glucagon in a glucose-dependent manner. U.S. labeling lists initial approval in 2017.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
New research links GLP-1 drugs like Ozempic to increased scurvy risk through appetite suppression and poor nutrition. University of Florida researchers are testing a GLP-1 implant for obese cats as feline obesity affects nearly 60% of US cats.
Abbott India will commercialize semaglutide, the diabetes drug behind Ozempic, under the brand name Extensior in India following a partnership with Novo Nordisk. The launch targets India's growing diabetes population of over 100 million people.
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Oral semaglutide and the newly FDA-approved Wegovy pill are reshaping weight management by eliminating injections. Clinical trials show meaningful weight loss, while companies integrate the medications into subscription wellness programs.
Novo Nordisk announced it will reduce list prices of Wegovy, Ozempic, and Rybelsus by 35% to 50% to $675 monthly starting in 2027, aiming to regain market share from rival Eli Lilly and improve access for high-deductible patients.
Novo Nordisk announced it will reduce the list price of its semaglutide products Ozempic, Wegovy and Rybelsus to $675 starting January 1, 2027, representing cuts of up to 50 percent from current pricing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07487103 |
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE3 |
| NCT05579977 |
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity |
TERMINATED | PHASE2 |
